Lilly's Diabetes and Weight-Loss Drugs Face Limited Supply for Most Dosages in Q2, FDA Reports

Gelonghui April 17 | The U.S. Food and Drug Administration (FDA) website shows that due to increased demand, most doses of Eli Lilly and Company's diabetes drug Mounjaro and weight-loss drug Zepbound will be in limited supply in the second quarter of this year. The supply of the 5 milligram (mg), 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses of these two drugs will be limited. The 2.5 mg dose is listed as available. Previously, some doses of these two drugs were expected to be in limited supply until April.